Vaxcyte, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Vaxcyte, Inc. | PCVX - NASDAQ |
$14.00-$16.00 | $16.00 | $20.80 | 15.625 million | 6/12/2020 |
| BofA Securities, Jefferies, Evercore ISI | ||||||
Co-Manager(s): Cantor, Needham & Company | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-05-22 Terms Added 2020-06-08 | ||||||
Vaxcyte, Inc. Quote & Chart - Click for current quote - PCVX
IPO Boutique aggregates information on public companies and private companies, such as "PCVX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Vaxcyte, Inc. (adapted from Vaxcyte, Inc. prospectus):
They are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PCVX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.